- Markets
- Healthcare
- SAKAR
SAKAR
New to Zerodha? Sign-up for free.
New to Zerodha? Sign-up for free.
-
Share Price
-
Financials
-
Revenue mix
-
Shareholdings
-
Peers
-
Forensics
- 5D
- 1M
- 6M
- YTD
- 1Y
- 5Y
- MAX
This data is currently unavailable for this company.
-
Summary
-
Profit & Loss
-
Balance sheet
-
Cashflow
This data is currently unavailable for this company.
(In Cr.) |
---|
(In Cr.) | ||||
---|---|---|---|---|
This data is currently unavailable for this company. |
(In %) |
---|
(In Cr.) |
---|
Financial Year (In Cr.) |
---|
-
Product wise
-
Location wise
Revenue Mix
This data is currently unavailable for this company.
Revenue Mix
This data is currently unavailable for this company.
Recent events
-
News
-
Corporate Actions
Sakar Healthcare Re-Appoints Sanjay S. Shah As MD
July 22 (Reuters) - Sakar Healthcare Ltd SAKA.NS:
SAKAR HEALTHCARE - RE-APPOINTS SANJAY S. SHAH AS MD
SAKAR HEALTHCARE - RE-APPOINTS AARSH S. SHAH AS JOINT MD
Further company coverage: SAKA.NS
(([email protected];))
July 22 (Reuters) - Sakar Healthcare Ltd SAKA.NS:
SAKAR HEALTHCARE - RE-APPOINTS SANJAY S. SHAH AS MD
SAKAR HEALTHCARE - RE-APPOINTS AARSH S. SHAH AS JOINT MD
Further company coverage: SAKA.NS
(([email protected];))
Sakar Healthcare Starts Product Dossier Submission To Overseas Countries
July 8 (Reuters) - Sakar Healthcare Ltd SAKA.NS:
SAKAR HEALTHCARE - STARTED PRODUCT DOSSIER SUBMISSION IN ANTI-CANCER SEGMENT TO OVERSEAS COUNTRIES
Source text for Eikon: ID:nNSE5Z7w0z
Further company coverage: SAKA.NS
(([email protected];))
July 8 (Reuters) - Sakar Healthcare Ltd SAKA.NS:
SAKAR HEALTHCARE - STARTED PRODUCT DOSSIER SUBMISSION IN ANTI-CANCER SEGMENT TO OVERSEAS COUNTRIES
Source text for Eikon: ID:nNSE5Z7w0z
Further company coverage: SAKA.NS
(([email protected];))
India's Sakar Healthcare jumps on oncology products' deal
** Shares of Sakar Healthcare SAKA.NS rise as much as 9.8% before trimming some gains, last up 1.4% at 341.75 rupees
** Pharma products maker said its oncology unit has entered into deal with seven overseas partners for supply of its oncology products
** Stock eyes busiest trading day since early March, volumes at 8.7x the 30-day avg
** Including session's gains, stock down ~15% so far this year
(Reporting by Manvi Pant in Bengaluru)
(([email protected]; +918447554364;))
** Shares of Sakar Healthcare SAKA.NS rise as much as 9.8% before trimming some gains, last up 1.4% at 341.75 rupees
** Pharma products maker said its oncology unit has entered into deal with seven overseas partners for supply of its oncology products
** Stock eyes busiest trading day since early March, volumes at 8.7x the 30-day avg
** Including session's gains, stock down ~15% so far this year
(Reporting by Manvi Pant in Bengaluru)
(([email protected]; +918447554364;))
Sakar Healthcare Says Sakar's Oncology Unit Receives EU Gmp Approval
March 6 (Reuters) - Sakar Healthcare Ltd SAKA.NS:
SAKAR'S ONCOLOGY (ANTI-CANCER) UNIT RECEIVES EU GMP APPROVAL
Source text for Eikon: [ID:]
Further company coverage: SAKA.NS
(([email protected];))
March 6 (Reuters) - Sakar Healthcare Ltd SAKA.NS:
SAKAR'S ONCOLOGY (ANTI-CANCER) UNIT RECEIVES EU GMP APPROVAL
Source text for Eikon: [ID:]
Further company coverage: SAKA.NS
(([email protected];))
Sakar Healthcare To Issue Shares, Warrants By Preferential Issue
Nov 21 (Reuters) - Sakar Healthcare Ltd SAKA.NS:
TO ISSUE SHARES AND WARRANTS BY WAY OF PREFERENTIAL ISSUE
TO ISSUE UP TO 400,000 SHARES AT ISSUE PRICE OF 384 RUPEES PER SHARE
TO ISSUE UP TO 500,000 WARRANTS AT ISSUE PRICE OF 384 RUPEES PER WARRANT
Source text for Eikon: ID:nNSE4nQLGH
Further company coverage: SAKA.NS
(([email protected];;))
Nov 21 (Reuters) - Sakar Healthcare Ltd SAKA.NS:
TO ISSUE SHARES AND WARRANTS BY WAY OF PREFERENTIAL ISSUE
TO ISSUE UP TO 400,000 SHARES AT ISSUE PRICE OF 384 RUPEES PER SHARE
TO ISSUE UP TO 500,000 WARRANTS AT ISSUE PRICE OF 384 RUPEES PER WARRANT
Source text for Eikon: ID:nNSE4nQLGH
Further company coverage: SAKA.NS
(([email protected];;))
Sakar Healthcare Approved Issuance Of Shares By Way Of Preferential Issue On Private Placement Basis
Aug 3 (Reuters) - Sakar Healthcare Ltd SAKA.NS:
APPROVED ISSUANCE OF SHARES BY WAY OF PREFERENTIAL ISSUE ON PRIVATE PLACEMENT BASIS
APPROVED TO CREATE, OFFER, ISSUE AND ALLOT UP TO 2.3 MILLION SHARES AT ISSUE PRICE OF 259.75 RUPEES PER SHARE
Source text for Eikon: ID:nNSE4fXKw9
Further company coverage: SAKA.NS
(([email protected];;))
Aug 3 (Reuters) - Sakar Healthcare Ltd SAKA.NS:
APPROVED ISSUANCE OF SHARES BY WAY OF PREFERENTIAL ISSUE ON PRIVATE PLACEMENT BASIS
APPROVED TO CREATE, OFFER, ISSUE AND ALLOT UP TO 2.3 MILLION SHARES AT ISSUE PRICE OF 259.75 RUPEES PER SHARE
Source text for Eikon: ID:nNSE4fXKw9
Further company coverage: SAKA.NS
(([email protected];;))
Sakar Healthcare Gets WHO GMP Approval For Oncology Injection Unit
July 5 (Reuters) - Sakar Healthcare Ltd SAKA.NS:
SAKAR HEALTHCARE LTD - WHO GMP APPROVAL RECEIVED FOR ONCOLOGY INJECTION UNIT AT VERTICALLY INTEGRATED ONCOLOGY PRODUCT MANUFACTURING SITE
Source text for Eikon: ID:nNSE1YyZ5y
Further company coverage: SAKA.NS
(([email protected];;))
July 5 (Reuters) - Sakar Healthcare Ltd SAKA.NS:
SAKAR HEALTHCARE LTD - WHO GMP APPROVAL RECEIVED FOR ONCOLOGY INJECTION UNIT AT VERTICALLY INTEGRATED ONCOLOGY PRODUCT MANUFACTURING SITE
Source text for Eikon: ID:nNSE1YyZ5y
Further company coverage: SAKA.NS
(([email protected];;))
Sakar Healthcare Entered Into Agreement With Ferring Pharmaceuticals And Bazell Pharma Llp
May 18 (Reuters) - Sakar Healthcare Ltd SAKA.NS:
ENTERED INTO AGREEMENT THIS CONSECUTIVE WEEK WITH FERRING PHARMACEUTICALS AND BAZELL PHARMA LLP
AGREEMENT FOR DEVELOPING NOVEL DRUG DELIVERY SYSTEM (NDDS) FOR TWO OF ONCOLOGY PRODUCTS
Source text for Eikon: ID:nNSE2WW3N5
Further company coverage: SAKA.NS
(([email protected];;))
May 18 (Reuters) - Sakar Healthcare Ltd SAKA.NS:
ENTERED INTO AGREEMENT THIS CONSECUTIVE WEEK WITH FERRING PHARMACEUTICALS AND BAZELL PHARMA LLP
AGREEMENT FOR DEVELOPING NOVEL DRUG DELIVERY SYSTEM (NDDS) FOR TWO OF ONCOLOGY PRODUCTS
Source text for Eikon: ID:nNSE2WW3N5
Further company coverage: SAKA.NS
(([email protected];;))
Sakar Healthcare Entered Into Agreement With Pharmaceutical Oriented Services
May 11 (Reuters) - Sakar Healthcare Ltd SAKA.NS:
ENTERED INTO AGREEMENT WITH PHARMACEUTICAL ORIENTED SERVICES
AGREEMENT FOR PROCESS OF DEVELOPMENT OF PATENT NON-INFRINGING FILM COATED TABLETS IN FOUR STRENGTHS
Source text for Eikon: ID:nNSE2NNHC9
Further company coverage: SAKA.NS
(([email protected];;))
May 11 (Reuters) - Sakar Healthcare Ltd SAKA.NS:
ENTERED INTO AGREEMENT WITH PHARMACEUTICAL ORIENTED SERVICES
AGREEMENT FOR PROCESS OF DEVELOPMENT OF PATENT NON-INFRINGING FILM COATED TABLETS IN FOUR STRENGTHS
Source text for Eikon: ID:nNSE2NNHC9
Further company coverage: SAKA.NS
(([email protected];;))
Events:
More Micro Cap Ideas
See similar 'Micro' cap companies with recent activity
Promoter Buying
Companies where the promoters are bullish
Capex
Companies investing on expansion
Superstar Investor
Companies where well known investors have invested
Popular questions
-
Business
-
Financials
-
Share Price
-
Shareholdings
What does Sakar Healthcare do?
Sakar Healthcare, an Indian pharmaceutical company, manufactures and markets a wide range of pharmaceutical formulations for domestic and international markets. It also provides contract manufacturing services for pharmaceutical companies in India.
Who are the competitors of Sakar Healthcare?
Sakar Healthcare major competitors are Gufic Biosciences, Caplin Point Lab, Bharat Parenterals, Prevest Denpro, Medicamen Biotech, Kilitch Drugs(India), Ind-Swift Lab.. Market Cap of Sakar Healthcare is ₹679 Crs. While the median market cap of its peers are ₹638 Crs.
Is Sakar Healthcare financially stable compared to its competitors?
Sakar Healthcare seems to be less financially stable compared to its competitors. Altman Z score of Sakar Healthcare is 4.66 and is ranked 6 out of its 8 competitors.
Does Sakar Healthcare pay decent dividends?
The company seems to be paying a very low dividend. Investors need to see where the company is allocating its profits. Sakar Healthcare latest dividend payout ratio is 0% and 3yr average dividend payout ratio is 0%
How has Sakar Healthcare allocated its funds?
Companies resources are allocated to majorly productive assets like Plant & Machinery
How strong is Sakar Healthcare balance sheet?
Balance sheet of Sakar Healthcare is strong. But short term working capital might become an issue for this company.
Is the profitablity of Sakar Healthcare improving?
The profit is oscillating. The profit of Sakar Healthcare is ₹14.86 Crs for TTM, ₹11.67 Crs for Mar 2024 and ₹12.76 Crs for Mar 2023.
Is the debt of Sakar Healthcare increasing or decreasing?
The debt of Sakar Healthcare is decreasing. Latest debt of Sakar Healthcare is ₹73.63 Crs as of Sep-24. This is less than Mar-24 when it was ₹78.67 Crs.
Is Sakar Healthcare stock expensive?
Yes, Sakar Healthcare is expensive. Latest PE of Sakar Healthcare is 45.67, while 3 year average PE is 37.13. Also latest EV/EBITDA of Sakar Healthcare is 16.75 while 3yr average is 16.51.
Has the share price of Sakar Healthcare grown faster than its competition?
Sakar Healthcare has given better returns compared to its competitors. Sakar Healthcare has grown at ~29.89% over the last 3yrs while peers have grown at a median rate of 12.01%
Is the promoter bullish about Sakar Healthcare?
Promoters stake in the company seems stable, and we need to go through filings and allocation of resources to gauge promoter bullishness. Latest quarter promoter holding in Sakar Healthcare is 53.58% and last quarter promoter holding is 53.58%.
Are mutual funds buying/selling Sakar Healthcare?
There is Insufficient data to gauge this.